News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center

Articles by Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center

Final Thoughts on the Management of mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Additional Emerging Therapies for Progressive mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Emerging Agents for Progressive mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Sequencing After Frontline I/O Based Regimen for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Clinical Trials for Relapsed/Refractory mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Upcoming Combination Trials for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

I/O Therapy After Progression on I/O for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Role of TKI After Progression on I/O for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Review of the COSMIC 021 Study for mRCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Introduction and Review of CheckMate 9ER for Metastatic RCC

ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy

October 23rd 2020

Latest Updated Articles

Role of TKI After Progression on I/O for mRCC
Published: October 23rd 2020 | Updated:
Emerging Agents for Progressive mRCC
Published: October 23rd 2020 | Updated:
Review of the COSMIC 021 Study for mRCC
Published: October 23rd 2020 | Updated:
I/O Therapy After Progression on I/O for mRCC
Published: October 23rd 2020 | Updated:
Introduction and Review of CheckMate 9ER for Metastatic RCC
Published: October 23rd 2020 | Updated:
$Clinical Trials for Relapsed/Refractory mRCC$
Clinical Trials for Relapsed/Refractory mRCC
Published: October 23rd 2020 | Updated:

Trending on OncLive

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies

TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma